Javier Carrión earned his degrees in Biology–Zoology (UCM) and Environmental Sciences (UAM) in 1997 and 2000, respectively. He completed his PhD at the UAM in 2007, carrying out his research at the Centro de Biología Molecular “Severo Ochoa” and receiving the Extraordinary Doctoral Award. He has participated in several scientific cooperation networks (RICET, AECID, PLATESA).
In 2010, he joined the Complutense University of Madrid under a Juan de la Cierva contract, where his research has focused on Neglected Zoonoses, particularly on Immunology and Control (vaccines and therapies). He is the author of 48 JCR‑indexed scientific publications and has an h‑index of 23. Through UCM’s international faculty mobility program, he has undertaken academic and scientific exchange activities at the Pedro Kourí Institute of Tropical Medicine (University of Havana, Cuba), the University of Antioquia (PECET group, Medellín, Colombia), and the Central University of Ecuador–Quito (International Center for Zoonoses).
He has supervised two doctoral theses and is co‑inventor of three patents related to leishmaniasis. He developed the HISAK70 formulation, designed both as a vaccine and as a therapeutic approach against multiple forms of leishmaniasis. He serves as Principal Investigator of the national research project “Optimized chemo‑immunotherapeutic strategies in nanoparticles for the treatment of cutaneous leishmaniasis”, in collaboration with Dr. Socorro Espuelas.
He is currently an Tenured Associate Professor in the Department of Animal Health at UCM, with three recognized research six‑year periods and two teaching five‑year periods. He teaches in the UCM Master’s Program in Virology and in the Veterinary Medicine degree, in the courses Infectious Diseases and Microbiology and Immunology, the latter of which he coordinates. In 2020 and 2025, he received the Teaching Excellence Diploma (DOCENTIA Program).
He is an evaluator for the Spanish State Research Agency (AEI), director of the ICPVet research group, and head of the Translational Research Group on Leishmaniasis at the i+12 Research Institute, Hospital Universitario 12 de Octubre.